arbutus biopharma stock price
Company Description. Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Bu... High High is the highest sales price the stock has achieved during the regular trading hours, the intra-day high. Low Low is the lowest sales price the stock has fallen to during the regular trading hours, the intra-day low. Close / Last Close is the period at the end of the trading session. Sometimes used to refer to closing price. 6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year. Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada. About Arbutus Biopharma. Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). Arbutus Biopharma Corporation is a biopharmaceutical company. The Company specializes in discovering, developing, and commercializing a portfolio of drug candidates for patients suffering from chronic hepatitis B infection. Arbutus Biopharma operates Canada. 52 Week High/Low 52 Week High is the highest sales price the stock has achieved during the regular trading hours during the most recent 52 week period. 52 Week Low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period. $ 5.48 / $ 2.35. Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. Company Profile. Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada. The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months. Analysts' Ratings History for Arbutus Biopharma Corp (NASDAQ:ABUS) issued its earnings results on Thursday, November, 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.11. Arbutus Biopharma Corp had a negative return on equity of 8.50% and a negative net margin of 1,192.92%. Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
$5.00 to $10.00